EpitogenX Lyme Assay Featured in New Peer-Reviewed Serosurveillance Study
EpitogenX Ltd is pleased to announce the publication of a new peer-reviewed study in which its Lyme assay was used as part of a multi-assay serological framework to investigate seroprevalence and seroconversion following tick exposure.
The study, titled “Seroprevalence and seroconversion of Lyme borreliosis among tick-bitten individuals: a multi-assay serosurveillance study” (Article link), evaluated multiple diagnostic platforms to assess individuals following tick bites.
The EpitogenX Lyme assay demonstrated strong performance, comparable with leading assays used in the clinical practice, in terms of sensitivity for detecting both seroprevalence and post-exposure seroconversion.
While this study did not include an evaluation of diagnostic specificity, previous study (Article link) have demonstrated the high specificity of the EpitogenX assay, driven by the use of carefully selected, epitope-engineered recombinant antigens.
Key Highlights
- Strong sensitivity in detecting seroprevalence and seroconversion
- Performance comparable with leading commercial assays
- High specificity demonstrated in independent studies
- Use of multiplexed epitopes from different key biomarkers
- Validation in real-world serosurveillance settings
For technical enquiries and partnerships:
📧 info@epitogenx.com | 🌐 www.epitogenx.com